summari morn report result
reflect solid progress compani turnaround effort
turnaround still underway encourag
sequenti improv zbh organ day-adjust growth
profil y/i rel
compani state goal deliv
weight averag market growth wamgr growth
modesti sequenti stack two-year basi
well beat consensu expect top-
bottom-lin look compani expect
underli revenu growth rang
better expect gross margin pressur
y/i due higher-cost inventori flow
oper margin midpoint
driven improv sale expect de-lever modestli
lower effect tax rate drive ep growth next year
in-lin consensu expect new
prior base ep estim pleas
see note date februari first look-
result outlook ahead expect detail look
quarter
revis estim reflect zbh organ growth
expect result outlook adjust
estim increas revenu estim
underli
underli reflect zbh improv organ
growth outlook lower expect fx headwind leav
ep estim unchang y/i
lower estim y/i
reflect modest ramp oper margin
previous model toward manag outlook deliv
least
continu page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort non-recur item
compani data secur llc estim reuter
continu previou page
result reflect sequenti improv deliv sale
y/i report y/i ex-fx came ahead estim ahead
consensu revenu ep guidanc provid manag previous
note expect deliv growth within wamgr segment knee drove beat
rel estim follow spine craniomaxillofaci cmf
modestli off-set hip sport extrem trauma set
dental line deliv ep y/i came ahead
consensu estim driven better-than-expect top-lin result higher gross margin lower
expens net-net good quarter underli top-lin growth y/i
growth ep driven new product introduct suppli stabil improv execut
knee franchis drove beat rel estim driven rosa persona famili
product knee sale versu compar
estim sequenti acceler driven sequenti acceler
america somewhat off-set deceler europ middl east
africa emea deceler asiapacif knee price slightli
lower sequenti versu volum healthi versu
driven rosa persona revis note rosa knee drove littl
overal global knee growth impli approxim sale estim
sequenti quarter furthermor persona revis well receiv track
ahead manag expect ceo bryan hanson note call expect persona
revis drive growth differ way mix shift asp benefit share gain zbh
revis share primari pull primari overal zbh knee out-performance
consist expect see note date januari check point
signific out-performance knee acceler stack two-year basi
hip miss estim expect new product contribut go forward hip sale
versu compar estim
sequenti acceler driven acceler asiapacif somewhat
off-set deceler emea deceler america hip
price wors sequenti versu volum modestli lower
versu recal recent launch avenir complet hip featur
short stem receiv posit feedback see good uptak believ system could drive
meaning growth within franchis anterior approach faster growth segment
hip market bryan hanson previous note call short stem would drive busi
market growth near-term combin rosa hip would potenti posit
drive market growth segment long-term contempl mako hip provid
concret timelin
much focu set franchis especi extrem set sale
versu compar estim set price improv modestli
sequenti basi versu volum versu
continu improv execut segment challeng past
benefit improv suppli level identifi set area would like
doubl given high-growth market focus build special invest
innov previous note area would consid tuck-in
acquisit bryan hanson expect busi mid-singl digit grower time note
could even deliv growth top-end rang look ahead key focu around
sport medicin extrem less trauma
spine dental busi perform continu improv underli basi spine
craniomaxillofaci cmf sale versu compar
estim spine cmf price roughli stabl versu volum
improv versu drive beat rel estim segment
sale improv stack two-year basi well impli sale forc integr dis-synergi
spine moder continu see benefit uptak cmf thorac product
dental sale versu compar estim
dental price improv sequenti flat y/i versu volum versu
franchis make progress work new market strategi portfolio
realign sale reorgan certain geographi also recent announc distribut
agreement benefit segment go forward well overal franchis
make progress underli basi still deliv market growth manag
acknowledg work need done two segment
expect deliv least oper margin deliv gross margin
better estim driven higher volum favor
time cost within quarter look ahead manag expect gross margin
pressur due flow-through higher cost inventori expect oper margin
mid-point model margin expans
approach note initi multi-year restructur plan
object reduc cost drive mix shift invest higher prioriti growth opportun
manag anticip initi deliv annual adjust pre-tax oper
expens save incur one-tim cost period
expect initi provid pathway invest futur growth acceler oper
margin least also re-organ sever busi drive enhanc
strateg align across key growth area modifi report
million fiscal year end decemb cost good gross sell gener adminstr research total oper oper incom interest expens incom incom incom tax provis net incom minor net adjust dilut share adjust ep excl gener adminstr oper incom ebitda excl gener adminstr oper incom restat effect relat revenu custom contract present net period pension postretir benefit cost sourc compani report factset secur llc estim medic technolog
price target
price target base approxim cash ep estim risk
thesi includ increas invest slower procedur volum growth price pressur disrupt
integr biomet
zimmer biomet share trade roughli discount large-cap med-tech peer group believ
discount continu narrow compani benefit leadership commercially-
driven ceo bryan hanson oper issu resolv pipelin begin fulli
warsaw indiana-bas zimmer biomet hold one world largest orthoped implant
manufactur compani global market leader billion reconstruct orthoped
implant busi hip knee implant togeth account roughli revenu
compani report sale billion
